UK-based Allergy Therapeutics has suffered a setback after phase 3 results from the B301 trial of its latest birch allergy product failed to reduce symptoms.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh